SCHEDULE 13D/A: MPM BioImpact and Affiliates Reduce Stake in Repare Therapeutics Below 5% Threshold

A group of investment entities and individuals led by MPM BioImpact LLC have significantly reduced their beneficial ownership in Repare Therapeutics Inc. through open market sales, falling below the 5% reporting threshold.

Summary

• MPM BioImpact LLC and its affiliated entities, including MPM BioVentures 2014, L.P., MPM BioVentures 2014 (B), L.P., MPM Asset Management Investors BV2014 LLC, and UBS Oncology Impact Fund L.P., along with individuals Ansbert Gadicke, Luke Evnin, and Todd Foley, filed Amendment No. 7 to their Schedule 13D.
• The filing reports open market sales of Common Shares of Repare Therapeutics Inc. by these filing persons.
• As a result of these sales, all filing persons collectively ceased to be beneficial owners of more than 5% of Repare Therapeutics Inc.'s Common Shares on January 17, 2025.
• The sales occurred between January 16, 2025, and January 27, 2025, with average prices ranging from $1.18 to $1.28 per share.
• Post-sales, the beneficial ownership percentages for key entities are: MPM BioVentures 2014, L.P. at 2.4% (1,018,345 shares), MPM BioVentures 2014 (B), L.P. at 0.2% (67,921 shares), MPM Asset Management Investors BV2014 LLC at 0.1% (35,052 shares), and UBS Oncology Impact Fund L.P. at 1.9% (819,924 shares).
• Ansbert Gadicke's aggregate beneficial ownership is reported as 4.6% (1,941,242 shares).
• The beneficial ownership calculation is based on 42,510,708 Common Shares outstanding as of November 1, 2024, as reported in the Issuer's Form 10-Q filed on November 7, 2024.

Sentiment

Score: 5

Explanation: The document is a factual report of a change in beneficial ownership due to open market sales, without explicit positive or negative commentary from the issuer or the filing parties beyond the transaction itself.

Negatives

• A significant institutional investor group, MPM BioImpact LLC and its affiliates, has reduced its stake in Repare Therapeutics Inc. below the 5% beneficial ownership threshold, which could be perceived negatively by the market.
• The reduction involved substantial open market sales of Common Shares over several trading days in January 2025.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The reduction of a significant institutional investor's stake could lead to concerns about the company's future prospects or valuation, potentially influencing stock price.

Key Dates

Keywords

Repare Therapeutics Inc., Schedule 13D/A, Beneficial Ownership, Stock Sales, Institutional Investor, MPM BioImpact, Common Shares, Equity Stake, SEC Filing